Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.67 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.63 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.57 |
| ▸ | MTOR | P42345 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1361813 | 0.84 | ALDH1A1 (0.64) | POLBNPSR1ALDH1A1MAPK1CYP2C19 | |
| SCHEMBL1346829 | 0.81 | L3MBTL1 (0.65) | POLBALDH1A1MAPK1TDP1SMN1; SMN2 | |
| SCHEMBL3997072 | 0.81 | ALDH1A1 (0.64) | POLBALDH1A1MAPK1CYP2C19TDP1 | |
| SCHEMBL3719058 | 0.81 | PKM (0.69) | POLBALDH1A1MAPK1 | |
| Hydrochloric Acid SCHEMBL7966700 | 0.81 | L3MBTL1 (0.63) | POLBALDH1A1MAPK1TDP1SMN1; SMN2 | |
| SCHEMBL4618073 | 0.81 | ALDH1A1 (0.62) | POLBNPSR1ALDH1A1MAPK1TDP1 | |
| SCHEMBL5813426 | 0.78 | ALDH1A1 (0.87) | POLBALDH1A1MAPK1MAPTPIK3CA | |
| SCHEMBL19359340 | 0.77 | L3MBTL1 (0.50) | POLBNPSR1ALDH1A1MAPT | |
| SCHEMBL29923049 | 0.77 | L3MBTL1 (0.50) | POLBNPSR1ALDH1A1MAPT | |
| SCHEMBL4616589 | 0.77 | SMN1; SMN2 (0.69) | POLBNPSR1ALDH1A1MAPK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7547779-B2 | Preparation of 1,6-disubstituted azabenzimidazoles as kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2009-06-16 | — | — | US | disclosed |
| US-20080234261-A1 | Preparation of 1,6-Disubstituted Azabenzimidazoles as Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2008-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234261-A1 | Preparation of 1,6-Disubstituted Azabenzimidazoles as Kinase Inhibitors | TNK2, ROCK1, ARHGDIB | POLB 1713/4885NPSR1 4337/4885ALDH1A1 4395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.